Double-blind, placebo-controlled, dose-escalating phase 1 trial of LCB10 0200 (GT-1) in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 30 May 2018
At a glance
- Drugs LCB10-0200 (Primary)
- Indications Gram-negative infections
- Focus Adverse reactions
- 30 May 2018 According to a Geom Therapeutics media release, this trial is expected to begin in 2H of 2018.
- 30 May 2018 According to a Geom Therapeutics media release, company plans to submit an IND to the FDA in 2H 2018.
- 27 Sep 2017 According to a Geom Therapeutics media release, the company is planning to initiate Phase 1 studies in 2018.